Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer

Inclusion Criteria:

* Patients must have histologically or cytologically confirmed non-small cell lung cancer
* All patients must have one of the following stages: Stage IA(T1NO), and IB T2NO), II \& IIIA (N2 negative)
* No prior chemotherapy or radiation therapy for non-small cell lung cancer
* Age \>18 years
* ECOG performance status \<2
* Patients must have acceptable organ and marrow
* Patient must be deemed surgically and medically resectable
* Men and women of childbearing potential must be willing to use effective contraception while on treatment and for at least 3 months thereafter.
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Patients may not be receiving any other investigational agents.
* Patients should not have received chemotherapy or radiotherapy within 3 months prior to entry to study.
* Patients with tumors involving the superior sulcus are not eligible.
* Patients must not have post-obstructive pneumonia or other serious infection at the time of registration or other serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
* Prior resection of lung cancer is allowed, if at least five years have elapsed between previous resection and registration.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Pregnant women are excluded from this study. Women of childbearing potential must have a negative pregnancy test.
* Known HIV-positive patients are excluded from the study.
* Patients with a history of known autoimmune disease are excluded from this study.